Patents Assigned to PEPTINOV SAS
  • Publication number: 20210395368
    Abstract: The present invention relates to a polypeptide which comprises or consists of—a first sequence consisting of at least 8 contiguous amino acid residues selected from within the sequence extending from amino acid residues 55 to 67 of the PD-L1 protein, and at most 30 contiguous amino acid residues selected from within the complete sequence of the PD-L1 protein; and/or—a second sequence consisting of at least 8 contiguous amino acid residues selected from within the sequence extending from amino acid residues 85 to 101 of the PD-L1 protein, and at most 30 contiguous amino acid residues selected from within the complete sequence of the PD-L1 protein; and/or—a third sequence consisting of at least 8 contiguous amino acid residues selected from within the sequence extending from amino acid residues 111 to 127 of the PD-L1 protein, and at most 30 contiguous amino acid residues selected from within the complete sequence of the PD-L1 protein; and/or—a fourth sequence consisting of at least 8 contiguous amino acid resi
    Type: Application
    Filed: March 5, 2019
    Publication date: December 23, 2021
    Applicants: Peptinov SAS, Conservatoire National des Arts et Metiers
    Inventors: Lucille DESALLAIS, Jean-Pierre SALLES, Jean-Fran9ois ZAGURY
  • Patent number: 10456456
    Abstract: The present invention relates to a pharmaceutical composition comprising, by way of active ingredient, at least one polypeptide comprising, or constituted by a sequence constituted by at least 8 contiguous amino acids and from at the most 30 contiguous amino acids chosen from within the interleukin-6 sequence and from at the most 30 contiguous amino acids chosen from within the complete IL-6 sequence.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: October 29, 2019
    Assignee: PEPTINOV SAS
    Inventors: Lucille Desallais, Matthieu Montes, Jean-Francois Zagury
  • Patent number: 9669077
    Abstract: The present invention relates to a pharmaceutical composition comprising, by way of active ingredient, at least one polypeptide comprising, or constituted by a sequence constituted by at least 8 contiguous amino acids and from at the most 30 contiguous amino acids chosen from within the interleukin-6 sequence and from at the most 30 contiguous amino acids chosen from within the complete IL-6 sequence.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: June 6, 2017
    Assignee: PEPTINOV SAS
    Inventors: Lucille Desallais, Mattieu Montes, Jean-Francois Zagury
  • Patent number: 9301997
    Abstract: The present invention relates to a pharmaceutical composition comprising as active substance, at least one compound comprising, or consisting of, a polypeptide which comprises, or consists of, at least 11 contiguous amino acids selected from X1-S-D-I-F-X2-G-E-P-X3-L-X4-P-X5-X6-X7-X8-X9-Q-L (SEQ ID NO: 13).
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: April 5, 2016
    Assignee: PEPTINOV SAS
    Inventors: Jean-François Zagury, Rojo Ratsimandresy
  • Publication number: 20140322161
    Abstract: The present invention relates to a pharmaceutical composition comprising, by way of active ingredient, at least one polypeptide comprising, or constituted by a sequence constituted by at least 8 contiguous amino acids and from at the most 30 contiguous amino acids chosen from within the interleukin-6 sequence and from at the most 30 contiguous amino acids chosen from within the complete IL-6 sequence.
    Type: Application
    Filed: August 9, 2012
    Publication date: October 30, 2014
    Applicant: PEPTINOV SAS
    Inventors: Lucille Desallais, Mattieu Montes, Jean-Francois Zagury